TD Cowen Downgrades Legend Biotech After Carvykti Sales Miss
TD Cowen cut Legend Biotech to Hold from Buy after weaker Carvykti sales, citing slower demand, safety concerns, and rising competition.
/ 4 items
#LEGN↓
FDA Signals Faster Drug Approvals for Multiple Myeloma — Positive Read for Legend Biotech
FDA draft guidance supports new approval endpoints in multiple myeloma, potentially speeding drug development and boosting prospects for Legend Biotech’s CARTITUDE-6.
Oppenheimer & H.C. Wainwright Bullish on LEGN, JBIO, CGEN
Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines.
J&J's MajesTEC-3 Data Creates Competitive Landscape in Multiple Myeloma Treatment
Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.